Takeda Presents New Phase 3 Data Showing Oveporexton Improves Daily Functioning, Cognition, and Sleep in Narcolepsy Type 1
Takeda has unveiled additional findings from its pivotal Phase 3 clinical development program for oveporexton (TAK-861) at SLEEP 2026, highlighting the investigational therapy’s potential to transform the treatment landscape for narcolepsy type 1 (NT1). The newly presented data demonstrate significant improvements in daily functioning, cognitive performance, and nighttime sleep quality among patients receiving oveporexton, reinforcing previously reported efficacy results and supporting its potential to become the first therapy to directly address the underlying cause of the disease.
Oveporexton is an oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling in patients with narcolepsy type 1. The disorder is characterized by a loss of orexin-producing neurons in the brain, resulting in a chronic neurological condition that affects wakefulness, sleep regulation, cognition, and overall quality of life. By targeting the root cause of orexin deficiency, oveporexton aims to move beyond symptom management and offer a more comprehensive therapeutic approach.
The latest findings were presented from two global, multicenter, placebo-controlled Phase 3 studies—FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002)—and provide further evidence that oveporexton may improve a broad range of symptoms experienced by people living with NT1.
Addressing the Underlying Cause of Narcolepsy Type 1
Narcolepsy type 1 is a lifelong neurological disorder caused by the loss of orexin-producing cells in the hypothalamus. Orexin, also known as hypocretin, is a neuropeptide that plays a critical role in maintaining wakefulness, regulating sleep-wake transitions, and supporting cognitive and emotional function.
The deficiency of orexin leads to a wide spectrum of symptoms that extend far beyond excessive daytime sleepiness. Patients frequently experience cataplexy, fragmented nighttime sleep, sleep paralysis, hallucinations, cognitive difficulties, impaired concentration, memory problems, and challenges performing daily activities.
Current treatment approaches generally focus on managing individual symptoms rather than correcting the biological defect responsible for the disease. As a result, many patients continue to experience significant impairment despite available therapies.
Oveporexton was specifically designed to restore orexin signaling by selectively activating orexin receptor 2, potentially addressing multiple manifestations of the disorder simultaneously.
According to Dr. Emmanuel Mignot, principal investigator of the FirstLight Phase 3 study, narcolepsy type 1 should be viewed as a 24-hour disease rather than a condition defined solely by excessive daytime sleepiness and cataplexy.
He noted that many patients struggle with cognitive dysfunction, disrupted nighttime sleep, and broader impacts on daily functioning. The latest results suggest that oveporexton may provide meaningful improvements across these interconnected aspects of the disease.
Comprehensive Phase 3 Program Demonstrates Broad Benefits
The newly reported findings came from analyses of secondary and exploratory endpoints in Takeda’s Phase 3 clinical program.
The FirstLight study evaluated twice-daily dosing regimens of 2 mg, 1 mg, and placebo, while the RadiantLight study assessed a twice-daily 2 mg dose compared with placebo.
Both studies were designed to measure not only traditional narcolepsy symptoms but also broader functional and quality-of-life outcomes that are important to patients.
The results revealed consistent improvements across multiple dimensions of disease burden, reinforcing the concept that restoring orexin signaling may have widespread therapeutic effects.
Significant Improvements in Daily Functioning
One of the most notable findings involved improvements in everyday functioning, a critical outcome for patients whose symptoms often interfere with work, education, social relationships, and personal responsibilities.
Researchers assessed functioning using the Functional Impacts of Narcolepsy Instrument (FINI), a validated tool designed to measure the real-world consequences of narcolepsy across several key domains.
Across all evaluated dose levels, oveporexton demonstrated statistically significant improvements compared with placebo after 12 weeks of treatment.
The benefits were observed across all six FINI domains:
- Tiredness
- Cognitive functioning
- Cataplexy
- Social activities
- Everyday activities
- Everyday responsibilities
Importantly, most patients receiving oveporexton reached or exceeded established normative thresholds for these domains, suggesting that many individuals experienced improvements approaching levels seen in healthy populations.
These findings indicate that the therapy may enable patients to participate more fully in daily life, reducing the functional limitations commonly associated with narcolepsy type 1.
Researchers emphasized that improved daily functioning represents a particularly meaningful outcome because it reflects the practical impact of treatment beyond traditional clinical measures.
Cognitive Benefits Highlight Potential Disease-Modifying Effects
Cognitive impairment is a frequently reported but often underrecognized symptom of narcolepsy type 1.
Many patients describe difficulties with attention, memory, concentration, decision-making, and executive functioning. These challenges can affect educational achievement, workplace performance, and overall quality of life.
The Phase 3 studies evaluated cognitive outcomes using both objective neuropsychological testing and patient-reported assessments.
According to the data presented, oveporexton produced measurable improvements in cognitive symptoms compared with placebo.
Researchers observed benefits across tests assessing attention, executive function, and memory, suggesting that restoration of orexin signaling may positively influence multiple cognitive domains.
The findings were further supported by patient-reported outcomes.
Within the FINI Cognitive Function domain, approximately 70% of patients receiving oveporexton reported no significant cognitive difficulties by the end of treatment.
By comparison, only about 15% of patients receiving placebo reported a similar level of cognitive well-being.
This substantial difference highlights the potential of oveporexton to address one of the most burdensome and disabling aspects of narcolepsy that often persists despite current treatment options.
The cognitive improvements observed in the studies may also reflect the broader physiological role of orexin in regulating attention, alertness, and higher-order brain functions.
Improvements in Nighttime Sleep Quality
Although narcolepsy is commonly associated with excessive daytime sleepiness, many patients also experience severely disrupted nighttime sleep.
Frequent awakenings, fragmented sleep patterns, vivid hallucinations, sleep paralysis, and abnormal rapid eye movement (REM) sleep regulation are common features of the disorder.
The exploratory analyses presented at SLEEP 2026 showed encouraging effects of oveporexton on nighttime sleep quality.
Across both Phase 3 studies, patients receiving oveporexton reported improvements in several sleep-related symptoms.
Most participants receiving active treatment reported no hallucinations or sleep paralysis during the study period, representing a meaningful improvement in symptoms that can be distressing and disruptive.
In addition, patients receiving the 2 mg twice-daily regimen experienced notable reductions in disturbed nighttime sleep compared with baseline measurements.
Researchers also observed changes in REM sleep patterns.
One of the hallmark features of narcolepsy type 1 is abnormal regulation of REM sleep, which can occur prematurely and contribute to symptoms such as cataplexy, sleep paralysis, and hallucinations.
Data from the studies indicated that the timing and structure of REM sleep shifted toward patterns typically observed in healthy individuals.
These findings suggest that oveporexton may help normalize fundamental aspects of sleep architecture by restoring orexin-mediated regulation of sleep-wake processes.
Moving Beyond Symptom Management
The comprehensive nature of the Phase 3 results highlights a potentially important shift in how narcolepsy type 1 may be treated in the future.
Historically, available therapies have targeted individual symptoms such as sleepiness or cataplexy. While these treatments can provide meaningful benefits, they often require multiple medications and may leave significant unmet needs.
By addressing the underlying orexin deficiency responsible for the disease, oveporexton has demonstrated improvements across multiple symptom domains simultaneously.
Sarah Sheikh, Head of Takeda’s Neuroscience Therapeutic Area Unit and Global Development, noted that narcolepsy type 1 cannot be adequately characterized by a single symptom.
She explained that Takeda designed its Phase 3 program specifically to evaluate the therapy’s impact across the broad spectrum of disease manifestations.
According to Sheikh, the positive results underscore the importance of developing treatments capable of addressing the holistic burden of narcolepsy rather than focusing solely on isolated symptoms.
She also acknowledged the contributions of patients, caregivers, healthcare providers, and investigators who participated in the clinical development program.
Regulatory Review Underway
The positive Phase 3 findings arrive at a critical time for Takeda, as oveporexton is currently under review by multiple regulatory agencies around the world.
If approved, the therapy could become the first orexin receptor agonist available for patients with narcolepsy type 1.
Such an approval would represent a major scientific milestone because it would introduce a treatment specifically designed to replace missing orexin signaling rather than merely managing downstream symptoms.
The potential availability of an orexin agonist has generated significant interest within the sleep medicine community, where many experts view orexin restoration as one of the most promising advances in narcolepsy treatment in decades.
Additional Data to Be Presented at SLEEP 2026
Takeda has indicated that additional analyses from the oveporexton development program will be presented during the conference.
These presentations include pooled analyses from previously reported Phase 3 results, further evaluation of the therapy’s effects on microsleeps, and research exploring the overall symptom burden experienced by individuals living with narcolepsy type 1 in the United States.
Microsleeps—brief, involuntary episodes of sleep that occur during wakefulness—are a significant safety concern for many patients and can interfere with activities such as driving, working, and studying.
Further insights into how oveporexton affects these episodes could provide additional evidence of its broader clinical value.
A Potential New Era in Narcolepsy Care
The latest findings from FirstLight and RadiantLight add to growing evidence that oveporexton may fundamentally change the treatment paradigm for narcolepsy type 1.
By improving daily functioning, cognitive performance, nighttime sleep quality, and other core symptoms while addressing the underlying biological cause of the disease, the therapy has demonstrated a level of comprehensive benefit rarely seen in narcolepsy research.
Should regulatory authorities ultimately approve oveporexton, it could become the first therapy capable of restoring orexin signaling and potentially redefining the standard of care for people living with narcolepsy type 1.
For patients who have long relied on treatments focused primarily on symptom control, the prospect of a therapy that targets the root cause of the disease offers new hope for more complete and sustained improvements in quality of life, independence, and overall functioning.
About Oveporexton (TAK-861)
Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address a broad spectrum of daytime and nighttime symptoms.
The United States Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for oveporexton, with a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Regulatory submissions for oveporexton are also under review in China and Japan, with additional submissions planned throughout the year. Oveporexton is an investigational compound that has not been approved for use by any regulatory authority.
About the FirstLight and RadiantLight Phase 3 Orexin Studies
FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries, with enrollment completed within six months.
The FirstLight study enrolled 168 participants randomized to one of three dosing arms (twice-daily 2mg, 1mg and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (twice-daily 2mg and placebo). More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.
As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
